Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $45.60 (5.75% downside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016Leerink SwannReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Wells Fargo & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015Citigroup Inc.Initiated CoverageNeutral -> Buy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015GuggenheimInitiated CoverageBuy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.53)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.10)($0.55)$4.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.40)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2 14($0.27)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014Q4($0.40)($0.43)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.87)($0.46)($0.62)
Q2 20162($0.76)($0.57)($0.67)
Q3 20163($0.80)($0.53)($0.65)
Q4 20163($1.38)($0.59)($0.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
DateHeadline
07/25/16 09:36 PMCan Shares Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $50? - Investor Newswire
07/23/16 08:09 AMEcor1 Capital LLC Decreased Stake in Five Prime Therapeutics INC (NASDAQ:FPRX) by $8.73 Million as Shares Rose - Press Telegraph
07/23/16 08:09 AMHays Advisory adds Five Prime Therapeutics Inc (FPRX) to its portfolio - TheFounders Daily
07/22/16 04:34 AMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Current Analyst Ratings - Fiscal Standard
07/21/16 04:14 PMFive Prime Therapeutics Inc (NASDAQ:FPRX) Price Volatility Hits An Elevated Level - CML News
07/21/16 01:03 PMETF’s with exposure to Five Prime Therapeutics, Inc. : July 21, 2016 -
07/21/16 07:37 AMEarnings Focus and Crowd Sourced Sentiment Review for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - TGP
07/21/16 07:37 AMFive Prime Therapeutics Inc Just Recorded A Sigfniciant Increase - Press Telegraph
07/20/16 05:27 PMIncreased Stock Volatility Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Engelwood Daily
07/20/16 04:28 AMTrading Performance and Target Watch for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
07/20/16 04:28 AMFive Prime Therapeutics, Inc. (NASDAQ:FPRX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 04:28 AMIs $50 Price Target Attainable For Five Prime Therapeutics, Inc. (NASDAQ:FPRX)? - Investor Newswire
07/19/16 10:09 AMFPRX Crosses Above Average Analyst Target
07/18/16 03:05 PMFive Prime Therapeutics to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 4 - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., July 18, 2016-- Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, ...
07/16/16 03:55 PMEcor1 Capital LLC Decreased Stake in Five Prime Therapeutics INC (NASDAQ:FPRX) by $8.73 Million as Shares Rose - Consumer Eagle
07/15/16 03:06 PMCan Five Prime Therapeutics Inc (NASDAQ:FPRX) Continue to Deliver Results? - Street Report
07/14/16 04:38 PMGSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime's Proprietary Protein Discovery Platform - [at noodls] - July 14, 2016 SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative ...
07/14/16 04:12 PMCrowd Rating and Earnings Recap for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Telanagana Press
07/14/16 04:12 PMFive Prime Therapeutics (FPRX) Says Glaxo (GSK) Exercised Right to Take Exclusive License of Proprietary Protein ... - StreetInsider.com
07/14/16 04:01 PM5:01 pm Five Prime Therapeutics announces that GSK (GSK) exercised its option to take an exclusive license to the IP related to a target under the respiratory diseases research collaboration between the com -
07/14/16 04:00 PMGSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime’s Proprietary Protein Discovery Platform - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., July 14, 2016-- Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative protein therapeutics, announced that ...
07/13/16 04:46 AMAnalyst Target and Average Rating Watch: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
07/12/16 04:16 PMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 04:08 PMStock on the Rise for the Quarter: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Engelwood Daily
07/11/16 04:08 PMStock Performance Rundown on: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
07/11/16 04:08 PMStrong Sell Calls For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) At 0 - Investor Newswire
07/09/16 03:49 PMAre Analysts Bullish Five Prime Therapeutics Inc (NASDAQ:FPRX) After Last Week? - Engelwood Daily
07/08/16 04:41 AMShares of Five Prime Therapeutics (FPRX) Sees Large Outflow of Money - TheFounders Daily
07/07/16 04:08 PMWall Street Ratings and Target Price Views on Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Telanagana Press
07/06/16 04:12 PMIs Buying Stock Like Five Prime Therapeutics Inc After Such Increase Winning Strategy? - Press Telegraph
07/06/16 08:47 AMFive Prime's FPA144 an Orphan Drug for gastric cancer
07/06/16 08:47 AMFive Prime (FPRX) Announces FDA Orphan Drug Designation for FPA144 to Treat Gastric Cancer
07/06/16 07:05 AMFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : July 6, 2016 -
07/05/16 03:57 PMFive Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer - Yahoo Finance
07/05/16 01:49 PMOppenheimer Bullish On Eiger Biopharmaceuticals Shares, Sees 71% Upside - Oppenheimer said Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) has lots of legs to run on given multiple data catalysts over the next 12–18 months and early human POC data in hepatitis D and hypoglycemia. Drug Pipeline Eiger's lead asset, Sarasar, is a farnesyltransferase inhibitor in development to treat hepatitis D. Eiger is also developing Exendin (9-39) as a treatment for hypoglycemia occurring after bariatric surgery, and Bestatin for pulmonary arterial hypertension and lymphedema. Oppenheimer noted that HDV infection leads to hepatitis D, which is the most aggressive form of hepatitis and has no FDA-approved treatments. Sarasar and IFN treatment decrease HDV RNA levels, and Eiger is investigating the optimum dose and combination regimen in various Phase 2 trials, expected to read out in 2016/2017. Related Link: Five Prime Therapeutics' FPA144 Receives FDA Orphan Drug ...Full story available on Benzinga.com
07/05/16 11:06 AMFive Prime Therapeutics' FPA144 Receives FDA Orphan Drug Status - Five Prime Therapeutics Inc (Nasdaq: FPRX) revealed that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to its FPA144 for gastric cancer treatment. That included cancer of the gastroesophageal junction in patients whose tumors over express FGFR2b. According to the company, FPA144 is an anti-FGF receptor 2b (FGFR2b) humanized monoclonal antibody in clinical development as ...Full story available on Benzinga.com
07/05/16 08:47 AMFive Prime (FPRX) Announces FDA Orphan Drug Designation for FPA144 to Treat Gastric Cancer - StreetInsider.com
07/05/16 08:41 AMFive Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer - [at noodls] - July 5, 2016 SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative ...
07/03/16 03:46 PMShare Performance Recap for: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
06/30/16 04:23 PMInvestor Ideas Adds #Technology, #Biotech and #Mining Stocks to Directories
06/29/16 09:05 PMFive Prime Therapeutics to Use Proprietary Protein Discovery Platform to Identify New Factors that
06/29/16 05:12 AMFive Prime Therapeutics Inc. (FPRX) Jumps 5.33% on June 28 - Equities.com
06/28/16 09:04 PMShare Update and Earnings Review for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
06/28/16 04:02 PMFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 04:00 PMStock Performance Focus on: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
06/27/16 04:00 PMEquity Research and Technical Review on Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Press Telegraph
06/27/16 04:00 PMStrong Sell Calls Recommendations For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) At 0 - Investor Newswire
06/27/16 04:00 PMFive Prime Therapeutics (FPRX) Partners with University of Minnesota Med School for HSC Development - StreetInsider.com
06/27/16 08:25 AMFive Prime Therapeutics to Use Proprietary Protein Discovery Platform to Identify New Factors that Generate Hematopoietic Stem Cells in Collaboration with the University of Minnesota Medical School - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., June 27, 2016-- Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, ...
06/25/16 07:56 AMStock Tracing Lower on the Week Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Engelwood Daily

Social

About Five Prime Therapeutics

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $47.90
  • 50 Day Moving Average: $43.02
  • 200 Day Moving Average: $39.86
  • P/E Ratio: 5.35
  • P/E Growth: 0.71
  • Market Cap: $1.27B
  • Beta: 4.44
  • Current Year EPS Consensus Estimate: $-2.21 EPS
  • Next Year EPS Consensus Estimate: $-3.69 EPS
Additional Links:
Five Prime Therapeutics (NASDAQ:FPRX) Chart for Wednesday, July, 27, 2016